SUNNYVALE, Calif., Nov. 19, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong issued a letter to shareholders as detailed below.
I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.
As was recently announced, we were able to strengthen the corporation's balance sheet by raising cash and reducing liabilities. These financing transactions were vital for the Company to pay certain vendors who are critical to on-going operations, as well as raise sufficient working capital to pursue our corporate strategy, as detailed below. Our management team and Board of Directors remain extremely dedicated to the overall success of the corporation. This is evidenced by every member working without cash consideration since Amarantus became public in the spring of 2011. This has allowed all available resources to be focused on product development.
With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investor
|SOURCE Amarantus BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved